American Journal of Kidney Diseases
Volume 52, Issue 6 , Pages 1035-1038 , December 2008

Racial Differences in Erythropoietin Responsiveness

  • James S. Kaufman, MD

      Affiliations

    • Corresponding Author InformationAddress correspondence to James S. Kaufman, MD, Renal Section (111-RE), VA Boston Healthcare System, 150 S Huntington Ave, Boston, MA 02130

References 

  1. Kausz AT, Solid C, Pereira BJ, Collins AJ, St. Peter W. Intractable anemia among hemodialysis patients: a sign of suboptimal management or a marker of disease. Am J Kidney Dis. 2005;45:136–147
  2. Petronis K, Carroll C, Held P, Port F. Effect of race on access to recombinant human erythropoietin in long-term hemodialysis patients. JAMA. 1994;271:1760–1763
  3. Tomson C, Edmunds M, Chambers K, Bricknell S, Feehally J, Walls J. Effect of recombinant human erythropoietin on erythropoiesis in homozygous sickle-cell anemia and renal failure. Nephrol Dial Transplant. 1992;7:817–821
  4. Lacson E, Rogus J, Teng M, Lazarus JM. Hakim RH: The association of race with eryhtropoietin dose in patients on long-term hemodialysis. Am J Kidney Dis. 2008;52:1104–1114
  5. Beutler E, West C. Hematologic differences between African-Americans and whites: the role of iron deficiency and alpha-thalassemia on hemoglobin levels and mean corpuscular volume. Blood. 2005;106:740–745
  6. Foley RN, Wang C, Ishani A, Collins AJ. NHANES III: Influence of race on GFR thresholds and detection of metabolic abnormalities. J Am Soc Nephrol. 2007;18:2575–2582
  7. McFarlane SI, Chen SC, Whaley-Connell AT, et al. Prevalence and associations of anemia of CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004. Am J Kidney Dis. 2008;4(suppl 2):S45–S55
  8. Collins AJ, Li S, St. Peter W, et al. Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%. J Am Soc Nephrol. 2001;12:2465–2473
  9. Ma JZ, Ebben J, Xia H, Collins AJ. Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol. 1999;10:610–619
  10. Madore F, Lowrie EG, Brugnara C, et al. Anemia in hemodialysis patients: variables affecting this outcome predictor. J Am Soc Nephrol. 1997;8:1921–1929
  11. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998;339:584–590
  12. Drueke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355:2071–2084
  13. Foley RN, Parfrey PS, Morgan J, et al. Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int. 2000;58:1325–1335
  14. Parfrey PS, Foley RN, Wittreich BH, et al. Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol. 2005;16:2180–2189
  15. Phrommintikul A, Haas SJ, Elsik M, Krum H. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet. 2007;369:381–388
  16. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355:2085–2098
  17. Zhang Y, Thamer M, Stefanik K, Kaufman J, Cotter DJ. Epoetin requirements predict mortality in hemodialysis patients. Am J Kidney Dis. 2004;44:866–876
  18. Szczech LA, Barnhart HX, Inrig JK, et al. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int. 2008;74:791–798
  19. Norris K, Mehrotra R, Nissenson AR. Racial differences in mortality and ESRD. Am J Kidney Dis. 2008;52:205–208

PII: S0272-6386(08)01432-7

doi: 10.1053/j.ajkd.2008.10.002

American Journal of Kidney Diseases
Volume 52, Issue 6 , Pages 1035-1038 , December 2008

Article Tools